CJC-1295 No DAC 2mg — 5 Vial Research Package
CJC-1295 No DAC 2mg 5 Vials is a lyophilized research peptide package for qualified laboratory research only. The key buying details are simple: 5 vials, 2mg per vial, $89.95 total, and $17.99 per vial.
- Verification: current COA, HPLC, and MS documents are available on this product page.
- Purity context: ≥99% listed purity; current COA shows 99.22% purity by HPLC.
- Identity context: No DAC CJC-1295 is commonly discussed as modified GRF 1-29; do not substitute DAC-modified specifications.
- Shipping: $14.99 USPS Priority shipping is standard; see the shipping policy.
- Use boundary: research use only; not for human or animal use.
Quick Facts & Key Specifications
This section answers the first scan question: what is being offered, in what format, and what documentation supports the product record?
| Product | CJC-1295 No DAC 2mg 5 Vials |
|---|---|
| Package format | 5 vials; 2mg per vial; lyophilized peptide material |
| Price context | $89.95 package total; $17.99 per vial |
| Purity context | ≥99% listed purity; current COA shows 99.22% purity by HPLC |
| Identity / sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ |
| Formula / mass | C152H252N44O42; approximately 3,367.9 g/mol |
| Verification | COA, HPLC, and MS documentation displayed on this page and retained in product tabs |
| Use boundary | Laboratory research only; not for human or animal use |
What Is This Peptide?
CJC-1295 No DAC is a 29-amino-acid peptide associated with modified GRF 1-29 research documentation. The “No DAC” designation is central to the product identity because it distinguishes this molecule from DAC-modified CJC-1295, which carries a drug-affinity-complex modification and has different mass, formula, and documentation requirements.
For this product page, the practical identity signals are the stated No DAC name, sequence, vial strength, lyophilized format, and current analytical documents for the same batch marker.
Research Snapshot: Current State of Research
This section gives research context without turning literature references into product-use claims. CJC-1295 No DAC appears in research contexts involving growth-hormone-releasing-hormone analog documentation, modified GRF 1-29 identity review, peptide-stability comparison, and analytical-method development.
Research status
Laboratory and analytical research context; not clinical, diagnostic, therapeutic, veterinary, or human-use guidance.
Research themes
No DAC identity, modified GRF 1-29 terminology, sequence-linked mass expectations, and HPLC/MS records.
Evidence boundary
Analytical documents support batch and identity review; they do not establish biological outcomes.
Indexed literature context: the CJC-1295 name appears in both long-acting DAC-form literature and analytical-method records. Those references provide compound-family and method context; the current product identity remains CJC-1295 No DAC / modified GRF 1-29, so DAC-form specifications should not be substituted.
- PubMed PMID 15817669 — CJC-1295 identification and GRF-receptor research context for the long-acting DAC-modified analog.
- PubMed PMID 16352683 — CJC-1295 long-acting GHRH-analog research record; included as CJC-family context, not as a No DAC identity record.
- PubMed PMID 17018654 — CJC-1295 pulsatile-secretion research record for the long-acting analog; included to distinguish DAC-form literature from this No DAC product.
- PubMed PMID 21204297 — Analytical identification of CJC-1295 in an unknown preparation.
- PubMed PMID 26879649 — Immunoaffinity LC-HRMS/MS identification of growth-hormone-releasing-hormone analogs in plasma.
Testing & Verification: HPLC, MS, COA, and Why Each Matters
This section explains how to read the testing stack. A COA summarizes batch-level information, HPLC gives chromatographic purity context, and MS supports identity review through mass-based evidence.
COA
Connects the CJC-1295 No DAC product record to a batch, reported purity, and document date.
HPLC
Shows separated peaks under the stated method and gives context for the listed 99.22% purity figure.
MS
Supports No DAC identity review by comparing mass-based evidence against the expected peptide record.
Why all three matter: batch traceability, purity, and identity are different questions. HPLC can support a purity value, MS supports identity context, and the COA ties those records to the stated batch.
Quality Assurance & Batch Documentation
This section keeps batch evidence in one place so readers do not have to hunt through repeated explanations. The same three current PDFs are also retained in the COA, HPLC, and MS product tabs.
| Document | Current version | What it supports |
|---|---|---|
| COA | USCL 070626 | Lot-level quality-control and purity documentation; current COA shows 99.22% purity by HPLC. |
| HPLC | USCL 070626 | Chromatographic purity review and peak-profile context for the listed batch record. |
| MS | USCL 070626 | Mass-spectrometry identity-support documentation for the named peptide material. |
CJC-1295 No DAC 2mg 5 Vials Certificate of Analysis — USCL 070626
Lot-level quality-control and purity documentation; current COA shows 99.22% purity by HPLC. The PDF is embedded below and retained in the product tabs for quick access.
CJC-1295 No DAC 2mg 5 Vials HPLC Chromatogram — USCL 070626
Chromatographic purity review and peak-profile context for the listed batch record. The PDF is embedded below and retained in the product tabs for quick access.
CJC-1295 No DAC 2mg 5 Vials Mass Spectrometry Document — USCL 070626
Mass-spectrometry identity-support documentation for the named peptide material. The PDF is embedded below and retained in the product tabs for quick access.
Complete Technical Specifications
| Common name | CJC-1295 No DAC |
|---|---|
| Alternative names | CJC-1295 without DAC; Modified GRF 1-29 |
| Compound type | Synthetic research peptide; modified growth-hormone-releasing-factor analogue |
| Amino-acid sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ |
| Amino acid length | 29 amino acids |
| CAS number | 863288-34-0 |
| Molecular formula | C152H252N44O42 |
| Molecular weight | Approximately 3,367.9 g/mol |
| PubChem CID | 56841945 (record indexed under the listed CAS number) |
| Appearance | White to off-white lyophilized peptide powder or compact cake, depending on freeze-drying conditions. |
| Storage context | Store refrigerated at 2–8°C unless the product label, COA, or laboratory protocol specifies otherwise; protect from light, moisture, and unnecessary temperature cycling. |
| Package format | Five sealed vials; 2mg per vial; lyophilized peptide material |
| Current documents | COA, HPLC, and MS documents marked USCL 070626 |
Educational Insights: Understanding CJC-1295 No DAC
Why “No DAC” changes the identity discussion
DAC-modified and No DAC CJC-1295 references are easy to confuse in catalogues and secondary summaries. For analytical review, the No DAC page should keep its own sequence, formula, mass, and documentation rather than borrowing from DAC-modified references.
Sequence map for the No DAC form
How the analytical evidence fits together
Frequently Asked Questions
What is CJC-1295 No DAC 2mg 5 Vials?
CJC-1295 No DAC 2mg 5 Vials is a research peptide product containing five sealed vials, with 2mg of lyophilized CJC-1295 No DAC material per vial, for qualified laboratory research and analytical review only.
Is CJC-1295 No DAC the same as DAC-modified CJC-1295?
No. The No DAC form is commonly associated with modified GRF 1-29 and must be reviewed using its own sequence, formula, mass, and analytical documentation rather than DAC-modified specifications.
What amino-acid sequence is listed for CJC-1295 No DAC?
The product record lists Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂.
How many amino acids are in CJC-1295 No DAC?
The listed modified GRF 1-29 sequence contains 29 amino-acid residues and includes C-terminal amidation represented as NH₂.
What PubChem identifier is listed for this record?
The technical table links to PubChem CID 56841945, the record indexed under the listed CAS number 863288-34-0.
Which batch and testing documents are available?
The current page shows a COA, an HPLC chromatogram, and an MS document marked USCL 070626 for the listed CJC-1295 No DAC product record.
What does HPLC show on a peptide product page?
HPLC separates compounds under a stated analytical method and provides chromatographic purity and peak-profile context for the reported product record.
What is MS used for?
Mass spectrometry supports identity review by comparing measured mass evidence with the expected molecular identity of the named peptide material.
Why are both HPLC and MS useful?
They answer complementary analytical questions: HPLC supports purity context, while MS supports molecular-identity context. Neither should be treated as a substitute for the other.
Why is a batch-specific COA important?
A batch-specific COA connects the product record to a particular lot, test date, reported purity result, and associated analytical document set for laboratory recordkeeping.
How is CJC-1295 No DAC supplied for research?
This product is supplied as lyophilized peptide material in five sealed 2mg research vials.
What does lyophilized peptide mean?
Lyophilization is a controlled freeze-drying process that removes water to create a dry peptide-material format for storage, transport, and laboratory handling.
Can analytical documents predict a biological result?
No. COA, HPLC, and MS documents support batch, purity, and identity review; they do not establish biological outcomes or provide application guidance.
Does this page provide dosing or human-use guidance?
No. This page provides research-only analytical and documentation information and does not provide dosing, clinical, diagnostic, therapeutic, veterinary, or human-use guidance.
